Completed PHASE2 INTERVENTIONAL 2-arm NCT05655715

Checkpoint Inhibitors and SBRT for MCRPC (CheckPRO)

Randomised Phase 2 Trial of Stereotactic Body Radiation Therapy, SBRT in Combination with Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer

Sponsor: Bristol-Myers Squibb

Conditions Castrate Resistant Prostate Cancer Metastatic Castration-resistant Prostate Cancer Prostate Cancer Metastatic Prostate Cancer Stage IV

Interventions Biopsies Ipilimumab Injection [Yervoy] Nivolumab Injection [Opdivo] Stereotactic body radiotherapy

Updated 4 times since 2023 Last updated: Oct 14, 2024 Started: Nov 25, 2019 Primary completion: Aug 30, 2024 Completion: Aug 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Castrate Resistant Prostate Cancer and Metastatic Castration-resistant Prostate Cancer, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 4 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Nov 2024 — Present [monthly]

Completed PHASE2

Status: Recruiting → Completed
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jan 2023 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Nov 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Herlev and Gentofte Hospital

Data source: Herlev and Gentofte Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Herlev, Denmark